Bromfenac

Drug Profile

Bromfenac

Alternative Names: AHR 10282B; Bromday; Bronuck; Duract; Natax; Nuckone; Prolensa; Remura; WAY-PEM 420; Xibrom; XiDay; Yellox

Latest Information Update: 21 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Wyeth
  • Developer Bausch & Lomb; Croma Pharma; ISTA Pharmaceuticals; Senju Pharmaceutical
  • Class Analgesics; Benzophenones; Bromobenzenes; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ocular inflammation; Ocular pain
  • Market Withdrawal Postoperative pain
  • No development reported Age-related macular degeneration
  • Discontinued Dry eyes; Dysmenorrhoea; Osteoarthritis

Most Recent Events

  • 15 Jun 2017 Bausch & Lomb completes a phase III trial in Ocular pain (In adults, In the elderly) in Spain (Ophthalmic) (EudraCT2015-002155-10)
  • 21 Feb 2017 Senju Pharmaceutical plans a phase I trial for Diabetic macular oedema in Japan (UMIN000026201)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Age-related-macular-degeneration(Adjunctive treatment) in USA (Ophthalmic, Liquid)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top